{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:07:29Z","timestamp":1779224849454,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd003443.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T00:00:00Z","timestamp":1425600000000}}],"reference-count":255,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003443.pub3","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T18:16:47Z","timestamp":1425665807000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Perphenazine for schizophrenia"],"prefix":"10.1002","volume":"2015","author":[{"given":"Benno","family":"Hartung","sequence":"first","affiliation":[{"name":"University Hospital D\u00fcsseldorf; Institute for Legal Medicine; Moorenstr. 5 D\u00fcsseldorf North Rhine Westphalia Germany 40225"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Sampson","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Institute of Mental Health University of Nottingham Innovation Park, Jubilee Campus Nottingham UK NG7 2TU"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Ismaninger Stra\u00dfe 22 M\u00fcnchen Germany 81675"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,3,6]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.14789\/pjmj.19.239","article-title":"The comparison of therapeutic effects of FK-880 (sulpiride) and perphenazine in schizophrenia by a double-blind controlled study","volume":"19","author":"Amakusa","year":"1973","journal-title":"Juntendo Igako"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/archpsyc.1961.01710100093011","article-title":"Five phenothiazine derivates. evaluation and toxicity studies","volume":"4","author":"Bennett","year":"1961","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0008|cit3","unstructured":"CATIE - Schizophrenia Trial National Institute of Mental Health (NIMH), NCT00014001"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0003|cit4","unstructured":"Addington D Impact of second generation antipsychotic drugs and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia Proceedings of the 164th annual general meeting of the American Psychiatric Association; 2011 May 14-18; Honolulu, Hawaii 2011"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0004|cit5","doi-asserted-by":"crossref","unstructured":"Addington DE Mohamed S Rosenheck RA Davis SM Stroup TS McEvoy JP Impact of second-generation antipsychotic drugs and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia Journal of Clinical Psychiatry 2011 75 80","DOI":"10.4088\/JCP.09m05258gre"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0005|cit6","unstructured":"Anon Antipsychotic medications for schizophrenia on equal footing in improving patients' thinking skills Science Update 2007 1"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0006|cit7","doi-asserted-by":"crossref","unstructured":"Ascher-Svanum H Nyhuis AW Faries DE Heiler L Kinon BJ Treatment discontinuation following randomization to open-label olanzapine, risperidone or typical antipsychotic drugs during a one-year treatment for schizophrenia Clinical Schizophrenia & Related Psychoses 2008 226 34","DOI":"10.3371\/CSRP.2.3.4"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0007|cit8","doi-asserted-by":"crossref","unstructured":"Bick P Knoesen N Castle D Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists Australasian Psychiatry 2007 465 9","DOI":"10.1080\/10398560701689186"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Essock SM Covell NH Davis SM Stroup TS Rosenheck RA Lieberman JA Effectiveness of switching antipsychotic medications American Journal of Psychiatry 2006 2090 5","DOI":"10.1176\/appi.ajp.163.12.2090"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Gutierrez-Suela F Selection of antipsychotic drugs in a psychiatric hospital based on the results of CATIE study Farmacia Hospitalaria 2008 83 90","DOI":"10.1016\/S2173-5085(08)70031-5"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Haddad PM Dursun S Selecting antipsychotic drugs in schizophrenia: lessons from CATIE Journal of Psychopharmacology (Oxford, England) 2006 332 4","DOI":"10.1177\/0269881106062765"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Hermes E Nasrallah H Davis V Meyer J McEvoy J Goff D The association between weight change and symptom reduction in the CATIE schizophrenia trial Schizophrenia Research 2011 166 70","DOI":"10.1016\/j.schres.2011.01.022"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Hermes E Rosenheck R Choice of randomization to clozapine versus other second generation antipsychotic drugs in the CATIE schizophrenia trial Journal of Psychopharmacology (Oxford, England) 2012 1194 200","DOI":"10.1177\/0269881112443744"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Hermes ED Sokoloff D Stroup TS Rosenheck RA Minimum clinically important difference in the positive and negative syndrome scale with data from the clinical antipsychotic trials of intervention effectiveness (CATIE) Journal of Clinical Psychiatry 2012 526 32","DOI":"10.4088\/JCP.11m07162"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Jin Y Pollock BG Coley K Miller D Marder SR Florian J Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking Journal of Clinical Pharmacology 2010 73 80","DOI":"10.1177\/0091270009343694"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003443.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1016\/S0924-977X(06)70830-6","article-title":"Neurocognitive efficacy in patients with chronic schizophrenia","volume":"16","author":"Keefe","year":"2006","journal-title":"European Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD003443.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial","volume":"64","author":"Keefe","year":"2007","journal-title":"ArchIves of General Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Levine SZ Rabinowitz J Ascher-Svanum H Faries D Lawson T Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study Value in Health 2011 14","DOI":"10.1016\/j.jval.2011.08.306"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Levine SZ Rabinowitz J Ascher-Svanum H Faries DE Lawson AH Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study Schizophrenia Research 2011 42 6","DOI":"10.1016\/j.schres.2011.09.018"},{"issue":"12","key":"10.1002\/14651858.CD003443.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0021|cit21","unstructured":"Lin LA Comparing antipsychotic treatments for schizophrenia: A health state approach Dissertation Abstracts International: Section B: The Sciences and Engineering 2012 863"},{"issue":"4","key":"10.1002\/14651858.CD003443.pub3-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/appi.ajp.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Meyer JM McEvoy JP Davis VG Goff DC Nasrallah HA Davis SM Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study Biological Psychiatry 2009 1013 22","DOI":"10.1016\/j.biopsych.2009.06.005"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Miller DD Caroff SN Davis SM Rosenheck RA McEvoy JP Saltz BL Extrapyramidal side-effects of antipsychotic drugs in a randomised trial British Journal of Psychiatry 2008 279 88","DOI":"10.1192\/bjp.bp.108.050088"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Nasrallah HA Metabolic findings from the CATIE trial and their relation to tolerability CNS Spectrums 2006 32 9","DOI":"10.1017\/S1092852900026663"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Olfson M Ascher-Svanum H Faries DE Marcus SC Predicting psychiatric hospital admission among adults with schizophrenia Psychiatric Services (Washington, D.C.) 2011 1138 45","DOI":"10.1176\/ps.62.10.pss6210_1138"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Penn DL Keefe RSE Davis SM Meyer PS Perkins DO Losardo D The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial Schizophrenia Research 2009 17 23","DOI":"10.1016\/j.schres.2009.08.016"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Perlick DA Rosenheck RA Kaczynski R Swartz MS Canive JM Lieberman JA Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial Schizophrenia Research 2010 118 25","DOI":"10.1016\/j.schres.2009.09.026"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11414-007-9101-3","article-title":"Employment outcomes in a randomized trial of second-generation antipsychotic drugs and perphenazine in the treatment of individuals with schizophrenia","volume":"35","author":"Resnick","year":"2008","journal-title":"Journal of Behavioural Health Services and Research"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Rosenheck R Swartz M McEvoy J Stroup TS Davis S Keefe RS Second-generation antipsychotic drugs: Reviewing the cost-effectiveness component of the CATIE trial Expert Review of Pharmacoeconomics & Outcomes Research 2007 103 11","DOI":"10.1586\/14737167.7.2.103"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Rosenheck RA Davis VG Davis SM Stroup S McEvoy J Swartz M Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial Schizophrenia Research 2009 12 8","DOI":"10.1016\/j.schres.2009.06.002"},{"issue":"12","key":"10.1002\/14651858.CD003443.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1176\/ajp.2006.163.12.2080","article-title":"Cost-effectiveness of second-generation antipsychotic drugs and perphenazine in a randomized trial of treatment for chronic schizophrenia","volume":"163","author":"Rosenheck","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0033|cit33","first-page":"243","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"48","author":"Schulte","year":"2006","journal-title":"Tijdschrift voor Psychiatrie"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Stroup S Appelbaum P Swartz M Patel M Davis S Jeste D Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial Schizophrenia Research 2005 1 8","DOI":"10.1016\/j.schres.2005.08.007"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0039|cit35","unstructured":"Stroup TS Comparison of ziprasidone versus other atypical drugs in prospectively defined, unresponsive patients Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0035|cit36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0036|cit37","doi-asserted-by":"crossref","unstructured":"Stroup TS Lieberman JA McEvoy JP Davis SM Swartz MS Keefe RSE Results of phase 3 of the CATIE schizophrenia trial Schizophrenia Research 2009 1 12","DOI":"10.1016\/j.schres.2008.10.011"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0037|cit38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study","volume":"164","author":"Stroup","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0038|cit39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developme","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophrenia Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/ajp.2007.164.3.428","article-title":"Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study","volume":"164","author":"Swartz","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD003443.pub3-BIB0041|cit41","first-page":"500","article-title":"What CATIE found: results from the schizophrenia trial","volume":"59","author":"Swartz","year":"May 2008","journal-title":"Psychiatry Online"},{"issue":"1-3","key":"10.1002\/14651858.CD003443.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2007.11.034","article-title":"The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study","volume":"100","author":"Swartz","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Tsai HT Caroff SN Miller DD McEvoy J Lieberman JA North KE A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial American Journal of Medical Genetics 2010 336 40","DOI":"10.1002\/ajmg.b.30981"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Wessels AM Bies RR Pollock BG Schneider LS Lieberman JA Stroup S Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study Journal of Clinical Pharmacology 2011 1587 91","DOI":"10.1177\/0091270010387604"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/archpsyc.1975.01760280093009","article-title":"Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controlled study of drug interaction","volume":"32","author":"Chouinard","year":"1975","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD003443.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/archpsyc.1977.01770200089011","article-title":"Phenothiazine-induced ECG abnormalities. Effect of a glucose load","volume":"34","author":"Chouinard","year":"1977","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1192\/bjp.113.505.1425","article-title":"A double-blind trial of amitriptyline-perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics","volume":"113","author":"Collins","year":"1967","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0048|cit48","unstructured":"Dehnel LL Vestre ND Schiele BC A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population Current Therapeutic Research, Clinical and Experimental 1968 169 76"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0049|cit49","unstructured":"Eckmann F Weber J No English version available unpublished manuscript 1984"},{"issue":"8","key":"10.1002\/14651858.CD003443.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1185\/03007997809110194","article-title":"Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial","volume":"5","author":"Fruensgaard","year":"1978","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.1552-4604.1964.tb00103.x","article-title":"The comparative effectiveness of amitriptyline, perphenazine, and their combination in the treatment of chronic psychotic female patients","volume":"4","author":"Hanlon","year":"1964","journal-title":"Journal of New Drugs"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF00403632","article-title":"The comparative effectiveness of eight phenothiazines","volume":"7","author":"Hanlon","year":"1965","journal-title":"Psychopharmacologia"},{"issue":"6","key":"10.1002\/14651858.CD003443.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0447.1993.tb03480.x","article-title":"Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations","volume":"88","author":"Hoyberg","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0054|cit54","first-page":"285","article-title":"Comparison of efficacy of zotepine and perphenazine in schizophrenia by double-blind, controlled study","volume":"2","author":"Imai","year":"1980","journal-title":"Shinkei Seishin Yakuri"},{"issue":"6","key":"10.1002\/14651858.CD003443.pub3-BIB0055|cit55","first-page":"465","article-title":"A comparison between the clinical effectiveness of a dibenzothiazepine derivative and a phenothiazine derivative in schizophrenia. A controlled double blind study using clotiapine (W 130) and perphenazine","volume":"11","author":"Itoh","year":"1969","journal-title":"Seishin Igaku"},{"issue":"4","key":"10.1002\/14651858.CD003443.pub3-BIB0056|cit56","first-page":"284","article-title":"Comparison of thiothixene and perphenazine in schizophrenic patients using double-blind technique","volume":"11","author":"Itoh","year":"1969","journal-title":"Seishin Igaku"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0057|cit57","first-page":"131","article-title":"Comparison of a butyrophenone derivative (methylperidol) and a phenothiazine derivative (perphenazine) in schizophrenic patients using double-blind technique: statistical analysis by sequential method and wilcoxon test","volume":"11","author":"Itoh","year":"1969","journal-title":"Seishin Igaku"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0058|cit58","first-page":"101","article-title":"Comparison of clinical effects of penfluridol, a long-acting oral neuroleptic, and perphenazine in schizophrenia using double-blind technique","volume":"4","author":"Itoh","year":"1976","journal-title":"Rinsho Hyoka"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0059|cit59","unstructured":"Bristol-Myers S A multicenter, randomized, double-blind study of flexible doses of aripiprazole versus perphenazine in the treatment of patients with treatment-resistant schizophrenia http:\/\/www.clinicalstudyresults.org\/ 2004"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0060|cit60","unstructured":"Gismondi R Meltzer H Kujawa M Carson W Stringfellow J Iwamoto T Aripiprazole versus perphenazine in treatment-resistant schizophrenia Proceedings of the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20\u201324; Paris, France 2004"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0061|cit61","unstructured":"Kane J Carson W Kujawa M Stringfellow J Marcus R Sanchez R Aripiprazole in treatment-resistant schizophrenia: a 6-week double- blind comparison study versus perphenazine Schizophrenia Research 2004 155 6"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0062|cit62","unstructured":"Kane J Carson WH Kujawa M Stringfellow J Marcus R Sanchez R Aripiprazole in treatment-resistant schizophrenia: A 6-week double-blind comparison study versus perphenazine Conference proceedings 2004 155 6"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0063|cit63","unstructured":"Kane J McQuade R Jody D Carson W Kujawa M Stringfellow J Aripiprazole in treatment-resistant schizophrenia: a 6-week double-blind comparison study vs perphenazine Conference proceedings: 12th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland 2004"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0064|cit64","doi-asserted-by":"crossref","unstructured":"Kane JM Meltzer HY Carson WH Jr McQuade RD Marcus RN Sanchez R. Aripiprazole Study Group Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine Journal of Clinical Psychiatry 2007 213 23","DOI":"10.4088\/JCP.v68n0206"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"McQuade R Jody D Kane J Carson W Kujawa M Stringfellow J Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia European Neuropsychopharmacology 2003 S326","DOI":"10.1016\/S0924-977X(03)92058-X"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Modell S Jody D Kujawa M Carson W Stringfellow J Iwamoto T Efficacy of aripiprazole and perphenazine in severe schizophrenia resistant to treatment with atypical antipsychotic drugs European Neuropsychopharmacology 2004 S265","DOI":"10.1016\/S0924-977X(04)80296-7"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0067|cit67","unstructured":"Sanchez R Meltzer HY Marcus RN Stringfellow J Carson WH Kane JM Aripiprazole versus perphenazine in Treatment - Resistant Schizophrenia Schizophrenia Bulletin 2005 502"},{"issue":"4","key":"10.1002\/14651858.CD003443.pub3-BIB0068|cit68","first-page":"519","article-title":"Clinical evaluation of clocapramine (clofekton) in schizophrenia: a double blind comparison of clocapramine, haloperidol and perphenazine","volume":"12","author":"Kurihara","year":"1983","journal-title":"Rinsho Seishin Igaku"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005053-196107000-00001","article-title":"The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness","volume":"133","author":"Kurland","year":"1961","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00005053-196101000-00010","article-title":"Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations","volume":"132","author":"Kurland","year":"1961","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1600-0447.1989.tb01305.x","article-title":"Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial","volume":"80","author":"Lepola","year":"1989","journal-title":"Acta Psychatrica Scandinavica"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0072|cit72","unstructured":"Eli Lilly Company HGBJ: olz v perphenazine Eli Lilly and Company 2001"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0920-9964(00)90763-1","article-title":"Olanzapine and perphenazine in schizophrenia","volume":"41","author":"Naukkarinen","year":"2000","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0074|cit74","first-page":"164","article-title":"Olanzapine versus perphenazine in the treatment of schizophrenia: a double-blind study","volume":"67","author":"Rimon","year":"2004","journal-title":"Schizophrenia research"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2007-1017093","article-title":"Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study","volume":"20","author":"Remvig","year":"1987","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0076|cit76","unstructured":"Sun Z Liu B Li Z Zhang D Clozapine combined with perphenazine in the treatment of schizophrenia Hebei Mental Health 2000 142 4"},{"issue":"4","key":"10.1002\/14651858.CD003443.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/030006058201000412","article-title":"Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study","volume":"10","author":"Takahashi","year":"1982","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1192\/bjp.129.6.547","article-title":"Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity","volume":"129","author":"Praag","year":"1976","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0079|cit79","first-page":"141","article-title":"Controlled study of risperidone in elderly treatment of first-episode schizophrenia","volume":"21","author":"Wang","year":"2008","journal-title":"Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD003443.pub3-BIB0080|cit80","first-page":"423","article-title":"Schizophrenia olanzapine and perphenazine in the treatment of positive symptoms","volume":"21","author":"Wang","year":"2008","journal-title":"Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD003443.pub3-BIB0081|cit81","first-page":"463","article-title":"Elderly first controlled study of quetiapine in the treatment of schizophrenia","volume":"21","author":"Wang","year":"2008","journal-title":"Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0083|cit82","first-page":"155","article-title":"Effects and side-effects of bromperidol in comparison with other antipsychotic drugs","volume":"78","author":"Woggon","year":"1978","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0082|cit83","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000468337","article-title":"Double-blind comparison of bromperidol and perphenazine","volume":"13","author":"Woggon","year":"1978","journal-title":"International Pharmacopsychiatry"},{"issue":"14","key":"10.1002\/14651858.CD003443.pub3-BIB0084|cit84","first-page":"119","article-title":"Aripiprazole orally disintegrating tablets in the treatment of schizophrenia in old age were observed","volume":"4","author":"Zhang","year":"2010","journal-title":"Chinese Journal of Modern Drug Application"},{"issue":"519","key":"10.1002\/14651858.CD003443.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1192\/bjp.115.519.173","article-title":"Penicillamine and schizophrenia - a clinical trial","volume":"115","author":"Affleck","year":"1969","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0447.1980.tb07085.x","article-title":"Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial","volume":"279","author":"Ahlfors","year":"1980","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0087|cit87","first-page":"1","article-title":"Current status of pharmacotherapy in schizophrenia","volume":"20","author":"Akimoto","year":"1966","journal-title":"Folia Psychiatrica et Neurologica Japonica"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0088|cit88","first-page":"267","article-title":"Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazine decanoate, flusipirilene, penfluridol, perphenazine enanthate and pipothiazine palmitate","volume":"25","author":"Angst","year":"1975","journal-title":"Arzneimittel Forschung"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0089|cit89","unstructured":"Anonymous Schizophrenic and other psychotic reactions Medical Letter 1966 15 6"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0090|cit90","first-page":"73","article-title":"Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double-blind method","volume":"2","author":"Asada","year":"1976","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0447.1973.tb08446.x","article-title":"Clinical experience with depot neuroleptics","volume":"246","author":"Bakke","year":"1973","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0092|cit92","doi-asserted-by":"crossref","unstructured":"Bandelow B Muller P Frick U Gaebel W Linden M Muller Spahn F Depressive syndromes in schizophrenic patients under neuroleptic therapy European Archives of Psychiatry and Clinical Neuroscience 1992 291 5","DOI":"10.1007\/BF02195978"},{"issue":"6","key":"10.1002\/14651858.CD003443.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1176\/ajp.127.6.827","article-title":"Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia","volume":"127","author":"Becker","year":"1970","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.0954-6820.1965.tb01883.x","article-title":"Perphenazine (trilafon) in the prophylaxis of nausea and vomiting following acute myocardial infarct","volume":"177","author":"Bjerkelund","year":"1965","journal-title":"Acta Medica Scandinavica"},{"issue":"47","key":"10.1002\/14651858.CD003443.pub3-BIB0095|cit95","first-page":"5445","article-title":"No English title available","volume":"35","author":"B\u00f6hlau","year":"1985","journal-title":"Therapiewoche"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0096|cit96","first-page":"337","article-title":"Perphenazine in obstetrics. Evaluation of its use to replace an analgesic","volume":"14","author":"Cannistra","year":"1959","journal-title":"Obstetrics and Gynecology"},{"issue":"3-4","key":"10.1002\/14651858.CD003443.pub3-BIB0097|cit97","first-page":"151","article-title":"Risperidone vs. perphenazine - a double-blind comparison and prolactine plasma levels","volume":"6","author":"Ceskova","year":"1994","journal-title":"Psychiatria Danubina"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0098|cit98","first-page":"50","article-title":"Efficacy and tolerability of risperidone in different dose levels","volume":"92","author":"Ceskova","year":"1996","journal-title":"Ceskoslovenska Psychiatrie"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2044.1981.tb08728.x","article-title":"Amitriptyline and perphenazine (triptafen DA) in chronic pain","volume":"36","author":"Clarke","year":"1981","journal-title":"Anaesthesia"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"Cohen H Trilafon in the treatment of chronically psychotic hospitalized patients Pr\u00fcfbericht, New York. E. Merck Darmstadt 1958","DOI":"10.1176\/ajp.115.5.452"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0364-7722(79)90048-1","article-title":"Metabolic interaction between amitriptyline and perphenazine in psychiatric patients","volume":"3","author":"Cooper","year":"1979","journal-title":"Neuro-Psychopharmacology"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/(SICI)1099-1077(200004)15:3<179::AID-HUP156>3.0.CO;2-N","article-title":"Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia","volume":"15","author":"Boer","year":"2000","journal-title":"Human Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF02245440","article-title":"A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients","volume":"114","author":"Dencker","year":"1994","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD003443.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3109\/08039487609097207","article-title":"A double-blind comparison study between penfluridol and perphenazine in acute schizophrenic patients","volume":"30","author":"Eklund","year":"1976","journal-title":"Nordisk Psykiatrisk Tidsskrift"},{"issue":"8","key":"10.1002\/14651858.CD003443.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/jps.2600710811","article-title":"Serum prolactin level increase in normal subjects following administration of perphenazine oral dosage forms: possible application to bioavailibility testing","volume":"71","author":"Erb","year":"1982","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"8","key":"10.1002\/14651858.CD003443.pub3-BIB0106|cit106","first-page":"534","article-title":"Double-blind comparison of two depot neuroleptics (perphenazine enanthate and flupentixol enanthate) in chronic schizophrenia","volume":"50","author":"Eufe","year":"1979","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0107|cit107","first-page":"653","article-title":"Treatment of choreic movements with perphenazine","volume":"33","author":"Fahn","year":"1972","journal-title":"Diseases of The Nervous System"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0108|cit108","unstructured":"Farzin D Hosseini SH Shafaat A A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia Iranian Journal of Medical Sciences 2005 59 62"},{"issue":"8","key":"10.1002\/14651858.CD003443.pub3-BIB0109|cit109","first-page":"515","article-title":"A double-blind comparison of haloperidol with perphenazine in acute psychiatric patients","volume":"11","author":"Fitzgerald","year":"1969","journal-title":"Current Therapeutic Research"},{"issue":"9","key":"10.1002\/14651858.CD003443.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/070674378803300906","article-title":"Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics","volume":"33","author":"Galdi","year":"1988","journal-title":"Canadian Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD003443.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1600-0447.1977.tb00170.x","article-title":"Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety","volume":"55","author":"Gerlach","year":"1977","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0112|cit112","first-page":"227","article-title":"Tardive dyskinesia:Pathophysiological mechanisms and clinical trials","volume":"14","author":"Gerlach","year":"1988","journal-title":"L'Encephale"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/ajp.121.2.179","article-title":"Clinical trial of a potentiated diketopiperazine derivative as a psychopharmacological agent for the treatment of psychotic patients","volume":"121","author":"Gerson","year":"1964","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0114|cit114","first-page":"7","article-title":"No English title available","volume":"25","author":"Gianelli","year":"1990","journal-title":"Rivista di Psichiatria"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0115|cit115","first-page":"60","article-title":"Controlled studies with thiothixene and perphenzine in schizophrenic psychoses","volume":"12","author":"Hadlik","year":"1970","journal-title":"Activitas Nervosa Superior"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0116|cit116","doi-asserted-by":"crossref","unstructured":"Hanlon T Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients Psychopharmacologia 1966 328 39","DOI":"10.1007\/BF00408332"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.1979.tb00900.x","article-title":"Plasma levels of perphenazine and its metabolites during simultaneous treatment with anticholinergic drugs","volume":"7","author":"Hansen","year":"1979","journal-title":"British Journal of clinical Pharmacology"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0118|cit118","first-page":"135","article-title":"Perphenazine (Fentazine) in the management of chronic schizophrenia","volume":"46","author":"Haran","year":"1960","journal-title":"Journal of the Irish Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0119|cit119","first-page":"163","article-title":"Comparison of perphenazine and P-5227 in chronic schizophrenics: clinical and EEG effects","volume":"9","author":"Holden","year":"1969","journal-title":"Journal of Clinical Pharmacology and the Journal of New Drugs"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1967.01730280102012","article-title":"Drug therapy of depression","volume":"17","author":"Hollister","year":"1967","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archpsyc.1974.01760070072011","article-title":"Specific indications for different classes of phenothiazines","volume":"30","author":"Hollister","year":"1974","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/archpsyc.1964.01720240093010","article-title":"Perphenazine (trilafon) metabolism in psychotic patients","volume":"10","author":"Huang","year":"1964","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0123|cit123","unstructured":"Jprn U An intervention study of optimizing algorism-based pharmacological treatment for schizophrenia http:\/\/www.umin.ac.jp\/ctr\/index.htm 2011"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0124|cit124","first-page":"1065","article-title":"Treatment of delirium tremens. A comparative evaluation of four drugs","volume":"33","author":"Kaim","year":"1972","journal-title":"Quarterly Journal of Studies"},{"issue":"8","key":"10.1002\/14651858.CD003443.pub3-BIB0125|cit125","first-page":"867","article-title":"Comparison of clinical efficacy of clocapramine and perphenazine for chronic schizophrenia by the double-blind study","volume":"3","author":"Kaji","year":"1974","journal-title":"Rinsyo Seisin Igaku"},{"issue":"9","key":"10.1002\/14651858.CD003443.pub3-BIB0126|cit126","first-page":"2440","article-title":"Drug therapy of acute schizophrenia","volume":"20","author":"Kawakita","year":"1965","journal-title":"Saishin Igaku"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/BF02316862","article-title":"Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose","volume":"105","author":"Kistrup","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.1968.tb02029.x","article-title":"A controlled seven year study of endocrine and other indices in drug treated chronic schizophrenics","volume":"206","author":"Kline","year":"1968","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.1985.tb08537.x","article-title":"Perphenazine decanoate vs. Perphenazine enanthate - efficacy and side-effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients","volume":"322","author":"Knudsen","year":"1985","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0130|cit130","doi-asserted-by":"crossref","unstructured":"Knudsen P Hansen LB Hojholdt K Larsen NE Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients Acta Psychiatrica Scandinavica. Supplementum 1985 29 40","DOI":"10.1111\/j.1600-0447.1985.tb08538.x"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0131|cit131","doi-asserted-by":"crossref","unstructured":"Knudsen P Hansen LB Hojholdt K Larsen NE Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients Acta Psychiatrica Scandinavica. Supplementum 1985 41 50","DOI":"10.1111\/j.1600-0447.1985.tb08539.x"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1176\/ajp.117.4.358","article-title":"A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics","volume":"117","author":"Kothari","year":"1960","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0133|cit133","unstructured":"Lapolla A A double-blind evaluation of chlorpromazine versus a combination of perphenazine and amitriptyline International Journal of Neuropsychiatry 1967 403 5"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0920-9964(97)00034-0","article-title":"Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients","volume":"26","author":"Levine","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00426949","article-title":"Effects of perphenazine injections on prolactin levels in plasma from schizophrenic women and men","volume":"57","author":"Lindholm","year":"1978","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD003443.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1176\/ajp.139.10.1329","article-title":"Interaction between antidepressants and perphenazine in psychiatric inpatients","volume":"139","author":"Linnoila","year":"1982","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD003443.pub3-BIB0137|cit137","first-page":"497","article-title":"Sleep in psychotic patients: a comparative clinical study","volume":"3","author":"Loprete","year":"1967","journal-title":"International journal of neuropsychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0139|cit138","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.114.2.173-a","article-title":"Perphenazine - a drug modifying consciousness","volume":"114","author":"Mason-Browne","year":"1957","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0138|cit139","first-page":"300","article-title":"Effect of perphenazine (trilafon) on modification of crude consciousness","volume":"18","author":"Mason-Browne","year":"1957","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0140|cit140","doi-asserted-by":"crossref","unstructured":"Mazurek I Loza B Lecyk A Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia European Neuropsychopharmacology 2003 S347","DOI":"10.1016\/S0924-977X(03)92108-0"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00000542-195801000-00012","article-title":"Control of postoperative vomiting with perphenazine (trilafone): a double-blind study","volume":"19","author":"Moore","year":"1958","journal-title":"Anesthesiology"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0142|cit142","unstructured":"M\u00fcller M Pharmacokinetik\/Bioavailibility Evaluation of Three Different perphenazine Formulations (Decentan) in 18 healthy volunteers E. Merck, Darmstadt 1994"},{"issue":"4","key":"10.1002\/14651858.CD003443.pub3-BIB0143|cit143","first-page":"404","article-title":"Clinical comparison of methophenazine and perphenazine in schizophrenia. A controlled study. Effects on the photomyoclonic threshold","volume":"9","author":"Nahunek","year":"1967","journal-title":"Activitas Nervosa Superior"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0144|cit144","first-page":"339","article-title":"Clinical experience with octoclothepin in psychoses. Comparasion with perphenazine","volume":"10","author":"Nahunek","year":"1968","journal-title":"Activitas Nervosa Superior"},{"issue":"5","key":"10.1002\/14651858.CD003443.pub3-BIB0145|cit145","first-page":"281","article-title":"A comparison of therapeutic effects of triperidol and perphenazine in schizophrenia","volume":"65","author":"Nahunek","year":"1969","journal-title":"Ceskoslovenska Psychiatrie."},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0146|cit146","first-page":"56","article-title":"Comparison of triperidol with perphenazine in schizophrenic psychoses. Effect on the photomyoclonic threshold","volume":"12","author":"Nahunek","year":"1970","journal-title":"Activitas Nervosa Superior"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0147|cit147","first-page":"247","article-title":"Comparison of the therapeutic effect of flupenthixol and perphenazine in schizophrenia","volume":"12","author":"Nahunek","year":"1970","journal-title":"Activitas Nervosa Superior"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0148|cit148","first-page":"11","article-title":"Clinical experience with clozapin","volume":"71","author":"Nahunek","year":"1975","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0149|cit149","first-page":"104","article-title":"Outline classification of neuroleptic drugs based on results of short-term control crossed studies in schizophrenia","volume":"72","author":"Nahunek","year":"1976","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0150|cit150","first-page":"25","article-title":"On the question of differences between therapeutic responses after particular neuroleptics in comparison to perphenazine in schizophrenics","volume":"77","author":"Nahunek","year":"1981","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0151|cit151","first-page":"154","article-title":"Controlled 'comparison' of perphenazine with perphenazine in schizophrenia - a methodical check of a double-blind cross-over design","volume":"22","author":"Nahunek","year":"1980","journal-title":"Activitas Nervosa Superior"},{"issue":"4","key":"10.1002\/14651858.CD003443.pub3-BIB0152|cit152","first-page":"423","article-title":"Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicentre study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden","volume":"90","author":"Nordic Dyskinesia Study Group","year":"1986","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0153|cit153","first-page":"952","article-title":"Perphenazine (Trilafon) in the treatment of pschoses","volume":"77","author":"O'Reilly","year":"1957","journal-title":"Canadian Medical Association Journal"},{"issue":"5","key":"10.1002\/14651858.CD003443.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1176\/ajp.123.5.607","article-title":"Perphenazine-amitriptyline in the treatment of schizophrenia","volume":"123","author":"Oltman","year":"1966","journal-title":"American Journal of Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD003443.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0278-5846(89)90013-4","article-title":"The relationship between perphenazine plasma levels and clinical response in acute schizophrenia","volume":"13","author":"Omerov","year":"1989","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0156|cit156","unstructured":"Opjordsmoen S Brunsvik S Melle I Dahl A Friis S Haahr U A comparison between novel and traditional antipsychotic drugs as first-line medication in early psychosis Second international conference on early psychosis"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1176\/ajp.121.12.1147","article-title":"Time-series frequency analysis, and electrogenesis of the EEGs of normals and psychotics before and after drugs","volume":"122","author":"Pfeiffer","year":"1965","journal-title":"American Journal of Psychiatry."},{"issue":"5","key":"10.1002\/14651858.CD003443.pub3-BIB0158|cit158","first-page":"317","article-title":"Intermittent pharmacotherapy in chronic schizophrenia","volume":"24","author":"Prien","year":"1973","journal-title":"Hospital and Community Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0159|cit159","first-page":"80","article-title":"A controlled clinical trial of amitriptyline added to perphenazine in the treatment of depressed schizophrenics","volume":"15","author":"Prusoff","year":"1979","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0028-1094349","article-title":"Preliminary study of perphenazine enanthate in the treatment of chronic schizophrenia","volume":"5","author":"Rapp","year":"1972","journal-title":"Pharmakopsychiatrie Neuropsychopharmakologie"},{"issue":"5","key":"10.1002\/14651858.CD003443.pub3-BIB0161|cit161","first-page":"665","article-title":"A double blind crossover study comparing haloperidol decanoate and perphenazine enanthate","volume":"39","author":"Rapp","year":"1986","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archpsyc.1967.01730250099014","article-title":"Competing voice messages. Effects of a message load and drugs on the ability of acute schizophrenics to attend","volume":"17","author":"Rappaport","year":"1967","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD003443.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/00005053-196805000-00005","article-title":"Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background","volume":"146","author":"Rappaport","year":"1968","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0165|cit164","unstructured":"Reznik I Sirota P Treatment of obsessive and compulsive symptoms in schizophrenia with SSRI's and neuroleptics: a randomized controlled trial 21st Congress of Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland, UK 1998"},{"issue":"4","key":"10.1002\/14651858.CD003443.pub3-BIB0164|cit165","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00004714-200008000-00004","article-title":"Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics","volume":"20","author":"Reznik","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD003443.pub3-BIB0166|cit166","first-page":"419","article-title":"Amitriptyline-perphenazine and doxepin in depressed outpatients: a controlled double-blind study","volume":"43","author":"Rickels","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00007611-197102000-00027","article-title":"Haloperidol for acute psychiatric emergencies. A double-blind comparison with perphenazine in acute alcoholic psychosis","volume":"64","author":"Ritter","year":"1971","journal-title":"Southern Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0168|cit168","first-page":"171","article-title":"Comparison of the therapeutic results of clothiapin and perphenazine in schizophrenia","volume":"13","author":"Rodova","year":"1971","journal-title":"Activitas Nervosa Superior"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0169|cit169","first-page":"94","article-title":"A blind comparison of clozapine and perphenazine in schizophrenics","volume":"15","author":"Rodova","year":"1973","journal-title":"Activitas Nervosa Superior"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/bmj.1.5076.922","article-title":"Trials of perphenazine in the prevention of postoperative vomiting","volume":"1","author":"Scurr","year":"1958","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0447.1993.tb03335.x","article-title":"Poor neuroleptic response in acutely exacerbated schizophrenic patients","volume":"87","author":"Shalev","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0172|cit172","doi-asserted-by":"crossref","unstructured":"Sharpley P Heistad G Schiele BC Comparison of butaperazine and perphenazine: a double-blind controlled study Psychopharmacology 1964 209 16","DOI":"10.1007\/BF00413243"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0173|cit173","doi-asserted-by":"crossref","unstructured":"Shiloh R Zemishlany Z Aizenberg D Valevski A Bodinger L Munitz H Mianserin or placebo as adjuncts to typical antipsychotic drugs in resistant schizophrenia International Clinical Psychopharmacology 2002 59 64","DOI":"10.1097\/00004850-200203000-00003"},{"issue":"5","key":"10.1002\/14651858.CD003443.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004850-200015050-00002","article-title":"Fluvoxamine augmentation of antipsychotic drugs improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study","volume":"15","author":"Silver","year":"2000","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0175|cit175","unstructured":"Simopoulos AM Pinto A Uhlenhuth EH Mcgee J Old wine in new bottles: decreased hostility in chronic psychotic inpatients treated with diphenylhydantoin (Dilantin) 5th World Congress of Psychiatry, Ciudad de Mexico 1971 526"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-0447.1970.tb02067.x","article-title":"A controlled trial of combined medications on behavioral and extrapyramidal effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1176\/ajp.116.5.392","article-title":"A graphic comparison of five phenothiazines","volume":"116","author":"Smith","year":"1959","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1176\/ajp.142.4.430","article-title":"The pharmacological treatment of delusional depression","volume":"142","author":"Spiker","year":"1985","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0179|cit179","unstructured":"Sun S Liu Y Long JL Wang L Venlafaxine extended release tablets on schizophrenia cognitive function] Google Translate Chinese Journal of Health Psychology [\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7] 2010 394 6"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0180|cit180","unstructured":"Sun J Xie S Nisu L Wang X Shang X acute schizophrenic inpatients converted to aripiprazole treatment efficacy and safety of] Google Translate Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66] 2010 179 81"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0181|cit181","first-page":"57","article-title":"Controlled comparative study of methylperidol and perphenazine in schizophrenic psychoses","volume":"12","author":"Svestka","year":"1970","journal-title":"Activitas Nervosa Superior"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0182|cit182","first-page":"93","article-title":"A comparison of pimozide with perphenazine in the treatment of acute schizophrenic psychoses","volume":"14","author":"Svestka","year":"1972","journal-title":"Activitas Nervositas Superior"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0183|cit183","first-page":"103","article-title":"Comparison of the short-term therapeutic effect of oxyprothepine and perphenazine in schizophrenic patients. A controlled study","volume":"15","author":"Svestka","year":"1973","journal-title":"Activitas Nervosa Superior"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0184|cit184","first-page":"165","article-title":"A controlled comparison of oxypertine and perphenazine in schizophrenic psychoses","volume":"16","author":"Svestka","year":"1974","journal-title":"Activitas Nervosa Superior"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0185|cit185","first-page":"208","article-title":"The position of trifluoperazine in the group of neuroleptics (a controlled clinical comparative study)","volume":"17","author":"Svestka","year":"1975","journal-title":"Activitas Nervosa Superior"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0186|cit186","first-page":"32","article-title":"Controlled cross over comparison of isofloxythepin and perphenazine in the treatment of schizophrenic psychoses","volume":"31","author":"Svestka","year":"1989","journal-title":"Activitas Nervosa Superior"},{"issue":"4","key":"10.1002\/14651858.CD003443.pub3-BIB0187|cit187","first-page":"276","article-title":"Controlled cross over comparison of carbamazepine with perphenazine in schizophrenic psychoses. 31st Annual Psychopharmacology Meeting (1989, Jesenik, Czechoslovakia)","volume":"31","author":"Svestka","year":"1989","journal-title":"Activitas Nervosa Superior"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0188|cit188","first-page":"145","article-title":"Therapeutic results in schizophrenic and schizoaffective psychoses with sulpiride (Eglonyl Alkaloid), as compared with perphenazine (Perfenazin Spofa)","volume":"86","author":"Svestka","year":"1990","journal-title":"Ceskoslovenska Psychiatrie"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/030006059702500104","article-title":"Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients","volume":"25","author":"Syvalahti","year":"1997","journal-title":"Journal of International Medical Research"},{"issue":"5","key":"10.1002\/14651858.CD003443.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-0028-1094631","article-title":"A comparative study of the longacting neuroleptics perphenazine enanthate and flusipirilene","volume":"12","author":"Tegeler","year":"1979","journal-title":"Pharmakopsychiatrie Neuropsychopharmakologie"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0191|cit191","unstructured":"Wang X Yin J Yang L Li W Wu G Double-blind controlled side reaction of the L-stepholidine the treatment of schizophrenia and Nursing Strategy Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66] 2001 204 6"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1192\/bjp.109.460.422","article-title":"Withdrawal of perphenazine in chronic schizophrenia","volume":"109","author":"Whittaker","year":"1963","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0193|cit193","doi-asserted-by":"crossref","unstructured":"Wolf J Janssen F Lublin H Salokangas RKR Allain H Smeraldi E A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA) Current Medical Research and Opinion 2007 2313 23","DOI":"10.1185\/030079907X225448"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0194|cit194","first-page":"351","article-title":"A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients","volume":"4","author":"Yagi","year":"1976","journal-title":"Rinsho Hyoka (Clinical Evaluation)"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0195|cit195","unstructured":"Zhong C Guozhang J Duochen W A double-blind comparison trial of 1-stepholidine and perphenazine in treatment of schizophrenia 7th World Congress of Biological Psychiatry, Berlin, Germany 2001"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0196|cit196","unstructured":"Zhu S Liu Y Sun S Wang L Psychological care on cognitive function in patients with chronic schizophrenia, the impact of (Google Translate) China Practical Medicine (\u4e2d\u56fd\u5b9e\u7528\u533b\u836f) 2009 190 2"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/ajp.117.2.97","article-title":"Treatment of schizophrenic reactions with phenothiazine derivates. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine and phenobarbital","volume":"117","author":"Casey","year":"1960","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0198|cit198","doi-asserted-by":"crossref","unstructured":"Covell NH Weissman EM Essock SM Weight gain with clozapine compared to first generation antipsychotic medications Schizophrenia bulletin 2004 229 40","DOI":"10.1093\/oxfordjournals.schbul.a007074"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0199|cit199","unstructured":"Ferziger R Alphs L Turner N Mao L Rodriguez S Dixon L A multicenter effectiveness study of paliperidone palmitate vs oral antipsychotic drugs for people with schizophrenia recently released from jail: Study rationale and methodology Neuropsychopharmacology 2010 S101 S2"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0200|cit200","unstructured":"Ferziger R Alphs L Turner N Mao L Rodriguez S Dixon L A multicenter effectiveness study of paliperidone palmitate vs oral antipsychotic drugs for people with schizophrenia recently released from jail: Study rationale and methodology Proceedings of the 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida 2010"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1176\/ajp.117.10.930","article-title":"Thresholds for drug-induced akathisia","volume":"117","author":"Freedman","year":"1961","journal-title":"Journal of American Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1176\/ajp.115.7.577","article-title":"Therapeutic implications of differential effects of new phenothiazine compounds","volume":"116","author":"Freyhan","year":"1959","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0033-3182(69)71755-8","article-title":"The differential prediction of response to two anti-psychotic drugs","volume":"10","author":"Goldstein","year":"1969","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cpt196782249","article-title":"Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients","volume":"8","author":"Hollister","year":"1967","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1600-0447.1971.tb02203.x","article-title":"A double-blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy","volume":"47","author":"Kellam","year":"1971","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0206|cit206","doi-asserted-by":"crossref","unstructured":"Mahmoud RA Engelhart LM Janagap CC Oster G Ollendorf D Risperidone versus conventional antipsychotic drugs for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care Clinical drug investigation 2004 275 86","DOI":"10.2165\/00044011-200424050-00004"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0207|cit207","unstructured":"NCT Decision aid to facilitate shared decision making during treatment in schizophrenia http:\/\/ClinicalTrials.gov\/show\/NCT01420575 2011"},{"issue":"25","key":"10.1002\/14651858.CD003443.pub3-BIB0208|cit208","first-page":"1682","article-title":"The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden","volume":"149","author":"Povlsen","year":"1987","journal-title":"Ugeskrift for Laeger"},{"issue":"12","key":"10.1002\/14651858.CD003443.pub3-BIB0209|cit209","first-page":"366","article-title":"Trilafon (perphenazine) and largactil (chlorpromazine) in chronic schizophrenia. A comparison","volume":"120","author":"Schulsinger","year":"1958","journal-title":"Ugeskrift for Laeger"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0924-977X(99)80301-0","article-title":"Subjective experiences of schizophrenic patients on atypical antipsychotic olanzapine and typical antipsychotic perphenazine","volume":"9","author":"Szafranski","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD003443.pub3-BIB0211|cit211","first-page":"315","article-title":"Differences in therapeutic effects of phenothiazine drugs","volume":"9","author":"Vinar","year":"1968","journal-title":"Agressolgie"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement [comment]","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0214|cit214","volume-title":"Psychiatrische Pharmakotherapie","author":"Benkert","year":"1996"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Trials in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0216|cit216","first-page":"436","article-title":"[The prognosis of dementia praecox - schizophrenia group - Google translate]","volume":"65","author":"Bleuler","year":"1908","journal-title":"Allgemeine Zeitschrift f\u00fcr Psychiatrie"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0217|cit217","unstructured":"BMJ Group and Pharmaceautical Press British National Formulary No. 63. Antipsychotic drugs BNF 2012"},{"issue":"4","key":"10.1002\/14651858.CD003443.pub3-BIB0218|cit218","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0219|cit219","unstructured":"Bundesverband der Pharmazeutischen Industrie (editors) No English title given Fachinformation Decentan 2001 1 4"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jnnp.60.6.604","article-title":"Schizophrenia","volume":"61","author":"Cannon","year":"1996","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0221|cit221","unstructured":"Cost-Effectiveness Analysis Registry (CEA) https:\/\/research.tufts-nemc.org\/cear4\/ accessed 11\/09\/13"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0222|cit222","article-title":"Cochrane Reviewers' Handbook","volume-title":"The Cochrane Library [database on disk and CDROM]","author":"Clarke","year":"2000"},{"issue":"3","key":"10.1002\/14651858.CD003443.pub3-BIB0223|cit223","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001717.pub2","article-title":"Depot perphenazine decanoate and enanthate for schizophrenia","author":"David","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/bjp.bp.106.028654","article-title":"Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy","volume":"191","author":"Davies","year":"2007","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0225|cit225","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Abstracts of the 8th International Cochrane Colloquium Cape Town, South Africa Cochrane Collaboration"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD003443.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0232|cit232","first-page":"124","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0234|cit234","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0236|cit236","unstructured":"ICH Expert Working Group ICH harmonised tripartite guideline: structure and content of clinical study reports International conference on harmonisation of technical requirements for registration of pharmaceuticals for huma use"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0237|cit237","first-page":"1","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume-title":"Controlled Clinical Trials","volume":"17","author":"Jadad","year":"1996"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0238|cit238","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"2-3","key":"10.1002\/14651858.CD003443.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotic drugs an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1192\/bjp.123.6.621","article-title":"The phenomenology of hallucinations as an aid to differential diagnosis","volume":"123","author":"Lowe","year":"1973","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0244|cit244","first-page":"23","article-title":"Cost of schizophrenia in England","volume":"10","author":"Mangalore","year":"2007","journal-title":"Journal of Mental Health Policy and Economics"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0247|cit247","unstructured":"National Collaborating Centre for Mental Health Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition) National Clinical Guideline Number 82 2010"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0249|cit249","volume-title":"Martindale. The Complete Drug Reference","author":"Parfitt","year":"1999"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2009.06.002","article-title":"Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial","volume":"113","author":"Rosenheck","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"issue":"5","key":"10.1002\/14651858.CD003443.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD003443.pub3-BIB0253|cit253","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1192\/bjp.107.450.862","article-title":"A simple and reliable subclassification of chronic schizophrenia","volume":"107","author":"Wing","year":"1967","journal-title":"British Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD003443.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD003443.pub3-BIB0255|cit255","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003443.pub2","article-title":"Perphenazine for schizophrenia","author":"Hartung","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003443.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:42:12Z","timestamp":1722321732000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003443.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,6]]},"references-count":255,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003443.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,6]]}}}